Denali Therapeutics Inc. Lease, Cost
Denali Therapeutics Inc. (DNLI) reported Lease, Cost of $4.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Denali Therapeutics Inc. lease, cost for the quarter ending 2026-06-30 was $4.71M, a 8.88% increase year-over-year.
- Denali Therapeutics Inc. lease, cost for the quarter ending 2026-03-31 was $3.99M, a 7.56% decline year-over-year.
- Denali Therapeutics Inc. lease, cost for the quarter ending 2025-06-30 was $4.32M.
- Denali Therapeutics Inc. lease, cost for the quarter ending 2025-03-31 was $4.31M.
- Denali Therapeutics Inc. lease, cost for fiscal 2025 was $17.75M, a 29.06% increase from fiscal 2024.
- Denali Therapeutics Inc. lease, cost for fiscal 2024 was $13.75M, a 10.55% increase from fiscal 2023.
- Denali Therapeutics Inc. lease, cost for fiscal 2023 was $12.44M, a 1.98% increase from fiscal 2022.
- Denali Therapeutics Inc. lease, cost for fiscal 2022 was $12.20M, a 8.93% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.71M 10-Q · filed 2026-08-06 | $8.69M 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | $3.99M 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | $17.75M 10-K · filed 2026-02-26 | |||||||
| 2025-06-30 | $4.32M 10-Q · filed 2026-08-06 | $8.64M 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | $4.31M 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | $13.75M 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | $12.44M 10-K · filed 2026-02-26 | |||||||
| 2022-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $6.65M derived: sum of 2 quarters · filed 2023-02-27 | $9.34M derived: sum of 3 quarters · filed 2023-02-27 | $12.20M 10-K · filed 2023-02-27 | ||||
| 2022-09-30 | $3.31M 10-Q · filed 2022-11-03 | $5.99M derived: sum of 2 quarters · filed 2022-11-03 | $8.86M 10-Q · filed 2022-11-03 | $11.63M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2022-06-30 | $2.69M 10-Q · filed 2022-08-08 | $5.55M 10-Q · filed 2022-08-08 | $8.32M derived: sum of 3 quarters · filed 2023-02-27 | $11.19M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2022-03-31 | $2.86M 10-Q · filed 2022-05-05 | $5.63M derived: sum of 2 quarters · filed 2023-02-27 | $8.50M derived: sum of 3 quarters · filed 2023-02-27 | $11.27M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $5.63M derived: sum of 2 quarters · filed 2023-02-27 | $8.41M derived: sum of 3 quarters · filed 2023-02-27 | $11.20M 10-K · filed 2023-02-27 | $11.22M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $2.86M 10-Q · filed 2022-11-03 | $5.64M derived: sum of 2 quarters · filed 2022-11-03 | $8.43M 10-Q · filed 2022-11-03 | $11.19M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $2.78M 10-Q · filed 2022-08-08 | $2.80M 10-Q · filed 2021-08-04 | $5.57M 10-Q · filed 2022-08-08 | $5.60M 10-Q · filed 2021-08-04 | $8.32M derived: sum of 3 quarters · filed 2023-02-27 | $11.16M derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-03-31 | $2.79M 10-Q · filed 2022-05-05 | $2.80M 10-Q · filed 2021-05-05 | $5.55M derived: sum of 2 quarters · filed 2023-02-27 | $8.38M derived: sum of 3 quarters · filed 2023-02-27 | $11.28M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $5.59M derived: sum of 2 quarters · filed 2023-02-27 | $8.49M derived: sum of 3 quarters · filed 2023-02-27 | $11.10M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $2.83M 10-Q · filed 2021-11-04 | $2.80M 10-Q · filed 2020-11-05 | $5.73M derived: sum of 2 quarters · filed 2021-11-04 | $8.34M 10-Q · filed 2021-11-04 | $8.30M 10-Q · filed 2020-11-05 | $11.13M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $2.90M 10-Q · filed 2021-08-04 | $5.50M 10-Q · filed 2021-08-04 | $8.29M derived: sum of 3 quarters · filed 2022-02-28 | $10.89M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $2.60M 10-Q · filed 2021-05-05 | $5.39M derived: sum of 2 quarters · filed 2022-02-28 | $7.99M derived: sum of 3 quarters · filed 2022-02-28 | $10.49M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.39M derived: sum of 2 quarters · filed 2022-02-28 | $7.89M derived: sum of 3 quarters · filed 2022-02-28 | $10.19M 10-K · filed 2022-02-28 | $10.20M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $2.60M 10-Q · filed 2020-11-05 | $5.10M derived: sum of 2 quarters · filed 2020-11-05 | $7.40M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $2.50M 10-Q · filed 2020-08-07 | $4.80M 10-Q · filed 2020-08-07 | ||||||
| 2019-03-31 | $2.30M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |